MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,432K
Free Cash flow
-$1,432K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable
Prepaid expenses
Share-based compensation expense
Negative Cash Flow Breakdown
Net loss
Accrued expenses and other curre...
Accrued research and development...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,755
-3,177
-799
-976
Gain from settlement of account payable
-
-
0
0
Share-based compensation expense
51
58
95
118
Accounts receivable
0
-1,000
900
-425
Prepaid expenses
-143
-129
-2
-76
Other current assets
0
0
0
-16
Accounts payable
1,140
-51
28
18
Accrued research and development costs
-122
-50
152
-26
Accrued expenses and other current liabilities
-889
915
-157
85
Net cash used in operating activities
-1,432
-1,176
-1,579
-264
Purchases of property and equipment
0
66
-
-
Net cash used in investing activities
0
-66
-
-
Proceeds from atm
0
825
251
1,826
Proceeds from private placement
0
-
0
0
Issuance costs paid for private placement
0
-
0
0
Net cash provided by financing activities
0
825
251
1,826
Effect of exchange rate changes on cash and cash equivalents
-
-
0
0
Net decrease in cash and cash equivalents
-1,432
-417
-1,328
1,562
Cash and cash equivalents, beginning of period
2,823
3,240
4,568
3,232
Cash and cash equivalents, end of period
1,391
2,823
3,240
4,568
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$1,432K
(-533.63%↓ Y/Y)
Accounts payable
$1,140K
(1483.33%↑ Y/Y)
Prepaid expenses
-$143K
(-448.78%↓ Y/Y)
Share-based compensation
expense
$51K
(-77.63%↓ Y/Y)
Net cash used in
operating activities
-$1,432K
(2.65%↑ Y/Y)
Canceled cashflow
$1,334K
Net loss
-$1,755K
(-0.11%↓ Y/Y)
Accrued expenses and
other current...
-$889K
(-5129.41%↓ Y/Y)
Accrued research and
development costs
-$122K
(-710.00%↓ Y/Y)
Buy us a coffee
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)